接受胶质母细胞瘤治疗的66岁及以上Medicare人群中不良事件的性别差异
本研究利用SEER-Medicare数据集,分析66岁及以上胶质母细胞瘤患者在治疗模式和不良事件上的性别差异。男性更常接受标准治疗(20% vs 女性17%),女性更常未接受治疗(26% vs 男性21%)。接受标准治疗的女性更易发生胃肠道和血液淋巴系统疾病,男性更易发生心脏和肾脏疾病。
要点
- 男性胶质母细胞瘤患者接受标准治疗的比例为20%,女性为17%。
- 女性患者未接受治疗的比例为26%,男性为21%。
- 接受标准治疗的女性更易发生胃肠道疾病(M/F OR=0.76)和血液淋巴系统疾病(M/F OR=0.79),男性更易发生心脏疾病(M/F OR=1.21)和肾脏疾病(M/F OR=1.65)。
核心结论
- 在66岁及以上胶质母细胞瘤患者中,不同治疗模式下的治疗接受情况和不良事件发生存在性别差异。
研究设计与样本
- 利用SEER-Medicare数据集,采用多变量逻辑回归计算校正人口学变量和Elixhauser合并症评分后的男性/女性比值比(M/F OR)及95%置信区间,评估不良事件的性别差异。
主要发现
- 男性胶质母细胞瘤患者接受标准治疗(手术联合同步放化疗)的比例为20%,女性为17%。
- 女性患者未接受治疗的比例为26%,男性为21%。
- 接受标准治疗的女性更易发生胃肠道疾病(M/F OR=0.76;95% CI 0.64-0.91,p=0.002)。
- 接受标准治疗的女性更易发生血液和淋巴系统疾病(M/F OR=0.79;95% CI 0.66-0.95,p=0.012)。
- 接受标准治疗的男性更易发生心脏疾病(M/F OR=1.21;95% CI 1.02-1.44,p=0.029)和肾脏疾病(M/F OR=1.65;95% CI 1.37-2.01,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GB) is the most common primary malignant brain tumor with the highest incidence occurring in older adults with a median age at diagnosis of 64 years old. While treatment often improves survival it brings toxicities and adverse events (AE). Here we identify sex differences in treatment patterns and AE in individuals ≥ 66 years at diagnosis with GB. METHODS: Using the SEER-Medicare dataset sex differences in adverse events were assessed using multivariable logistic regression performed to calculate the male/female odds ratio (M/F OR) and 95% confidence intervals [95% CI] of experiencing an AE adjusted for demographic variables and Elixhauser comorbidity score. RESULTS: Males with GB were more likely to receive standard of care (SOC; Surgery with concurrent radio-chemotherapy) [20%] compared to females [17%], whereas females were more likely to receive no treatment [26%] compared to males [21%]. Females with GB receiving SOC were more likely to develop gastrointestinal disorders (M/F OR = 0.76; 95% CI,0.64-0.91, p = 0.002) or blood and lymphatic system disorders (M/F OR = 0.79; 95% CI,0.66-0.95, p = 0.012). Males with GB receiving SOC were more likely to develop cardiac disorders (M/F OR = 1.21; 95% CI,1.02-1.44, p = 0.029) and renal disorders (M/F OR = 1.65; 95% CI,1.37-2.01, p < 0.001). CONCLUSIONS: Sex differences for individuals, 66 years and older, diagnosed with GB exist in treatment received and adverse events developed across different treatment modalities.
引用
- Dmukauskas M, Cioffi G, Waite KA, et al. Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment. J Neurooncol. 2024. PMID: 38563855. doi:10.1007/s11060-024-04652-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。